Hi and welcome to Managing Myeloma. My name is Dr. Sagar Lonial, and I am a Professor at the Winship Cancer Institute of Emory University in Atlanta, Georgia. Another great question that I am often asked is, “How do we determine which patients will benefit the most from treatment with daratumumab and elotuzumab?” And I think some of that is going to be driven by a lot of the data that is emerging, both at the ASCO meeting in 2016 as well as at ASH, and in the coming years. Because what we know about monoclonal antibodies from many other clinical trials and many other clinical settings is that they seem to be additive to pretty much any other therapy that is available. So, I think what we are going to see is the addition of monoclonal antibodies to induction therapy, to consolidation therapy, and to maintenance therapy, and I think understanding which drug may be better suited for each of these different phases of treatment will depend on the clinical data. So far, we have just a few small trials. There is emerging data on randomized phase 3s, both with elotuzumab and daratumumab, that is coming in an induction therapy setting in combination with bortezomib and in combination with lenalidomide in larger phase 3 trials, and these will be critical to better answering those questions. Thank you for your attention and please tune into ManagingMyeloma.com for additional FAQs.

Reviewed on January 17, 2017 for clinical relevance.